• Market Access in European Union Countries: Pricing and Reimbursement of New Healthcare Technologies

    A major aim of health policy in most EU member countries is to regulate and control the price of, access to and the use of new and expensive medical technology. Despite this common objective, there are great differences in the means used to achieve it, because healthcare, pricing and reimbursement systems as well as domestic industry and economic...

    READ MORE
  • Cardiac CT: A Snapshot of Coming Developments

    The primary reason for the development of cardiac CT was the expectation that CT could replace diagnostic cardiac catheterisation procedures, an expensive study that, due to the need for arterial catheterisation, has a relatively high complication rate. But where will this relatively new technology go, and how will it improve imaging techniques for...

    READ MORE
  • Setting Up a Heart Failure Clinic: Ensuring Operational Efficiency

    Why was it Decided to Set Up a Heart Failure Clinic at the UZ Middelheim? This hospital is a university affiliated facility with a large interventional cardiovascular programme of more than 4,000 diagnostic coronary angiograms, and more than 2,000 PCIs per year. Over the years, improved prognosis of acute coronary syndromes has led to an increased...

    READ MORE
  • Marketing Your Healthcare Services: What You Need to Know

    Healthcare’s once-upon-a-time days are gone. Simply being the nearby hospital does not automatically stake your organisation’s financial claim. So, in an increasingly competitive industry, what is the ideal way to market a hospital or healthcare service to consumers—who are often no longer just patients? Throughout Europe, healthcare has to...

    READ MORE
  • Anticlotting Medicine Lowers Incidence of Heart Attack

    New data shows anticlotting medicine Tirofiban (AGGRASTAT®) lowers incidence of heart attack in patients who respond poorly to aspirin or Clopidogrel after elective coronary angioplasty. Dr Marco Valgimigli, Chair of Cardiology, University of Ferrara, Italy and the principal investigator of the study emphasised the significance of the findings as they...

    READ MORE
  • Physio-Control Receives FDA Clearance for Life Pak 20e Defibrillator/Monitor Within the US

    Physio-Control, a wholly owned subsidiary of Medtronic Inc. received clearance from the FDA on October 3, 2008 to market the LIFEPAK 20e defibrillator / monitor within the US. It is an enhancement of the LIFEPAK 20 with a more powerful lithium-ion battery doubling ECG monitoring time. It is a non-evasive way to monitor the oxygenisation of a patient’s...

    READ MORE
  • Pfizer Research Reshuffle

    The Wall Street Journal has reported that Pfizer have abandoned the development of medicines for heart diseases. In the past Pfizer dominated the cardiovascular drugs sector with Lipitor being named as the worlds best selling drug in 2007. Due to a reorganisation of research they will be leaving drugs such as Lipitor to focus on other programmes including...

    READ MORE
  • Trials Show CRT Delays First Hospitalisation

    Medtronic sponsored trials by REVERSE and PARTNERS HF have shown that cardiac resynchronisation therapy (CRT) delays the time to the first hospitalisation or death in patients with mild heart failure, and devices equipped with OptiVol® Fluid Status Monitoring identified patients who were at a significantly higher risk of having heart failure events...

    READ MORE
  • WHO Governing Body to Make Decisions Affecting Health Systems

    The need to strengthen health systems so that they can respond quickly and flexibly to the growing number of new challenges was on the agenda of the WHO’s European governing body, the WHO Regional Committee for Europe. Attended by over 250 health officials from the WHO European Region, its annual session took place in Tbilisi, Georgia from September...

    READ MORE
Subscribe To The Cardiology Management Channel